KLRA - CIK 0002096997
Kailera Therapeutics, Inc. has filed 52 documents with the SEC between 2025 and 2026. The most frequent type is new insider ownership (20 filings), alongside the regular cadence of annual reports, quarterly reports, and event disclosures every public company must make. Use the filters to focus on one filing type, or flip the sort to trace the company's history from its earliest paperwork.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Filing | Type | Filed | Period covered |
|---|---|---|---|
| 424B4 | - | 2026-04-17 | - |